Skip to main content

Home/ Health affairs/ Group items matching "latest-pharmacy-updates" in title, tags, annotations or url

Group items matching
in title, tags, annotations or url

Sort By: Relevance | Date Filter: All | Bookmarks | Topics Simple Middle
pharmacybiz

Diamorphine 5mg And 10mg Powder Face Supply Disruption - 0 views

  •  
    Diamorphine 5mg and 10mg powder used for solution for injection ampoules will remain unavailable until February 2022, Department of Health and Social Care (DHSC) has said in an update. These injection ampoules are used to treat severe pain associated with surgical procedures, pain in the terminally ill, and to provide relief in acute pulmonary oedema. Diamorphine 30mg and 100mg ampoules are available, however, the stock is not enough to support an uplift in demand. Separately, the DHSC has extended the Medicine Supply Notification for Kolanticon gel, which is expected to remain unavailable until October 2022.
pharmacybiz

Randox Amends Terms After CMA Raises Concerns - 0 views

  •  
    Following concerns raised by the competition watchdog, UK PCR testing provider Randox has improved its terms on cancellations, refunds and liability. The development is part of the Competition and Markets Authority's (CMA) ongoing engagement in the PCR tests sector. The CMA has also sent letters to 25 PCR providers, warning them to review their terms and conditions or risk facing enforcement action. It currently has formal investigations open into two PCR providers, Expert Medicals and Dante Labs. Randox, one of the largest providers in the sector, has reviewed its its terms and conditions and changed them to: Give clearer information to customers, in particular on when it will provide PCR tests and resultsImprove notification of customers' legal rights on cancellations and refunds Remove terms that could suggest customers aren't entitled to compensation if things go wrong
pharmacybiz

David Wright: HRA Pharma's former CEO joins Ceuta Group - 0 views

  •  
    Ceuta Group, a global brand building business providing end-to-end outsourcing services in the health and wellness industry has appointed David Wright as a non-executive board director. With extensive experience of leading global consumer healthcare companies, David joins Ceuta Group following five years as CEO/President of global pharmaceutical company, HRA Pharma and six years as Global Head of Boehringer Ingelheim's consumer business. During his time at HRA Pharma and Boehringer Ingelheim GmBH, David led both companies through substantial organisational and strategy re-design which led to sustainable growth and profitability. The company said: "David has a strong belief that combining the right structure, operational priorities and processes, with a strong focus on company culture, are critical factors in building successful businesses. This approach saw him lead a period of transformation at HRA Pharma resulting in the company's successful acquisition by Perrigo Company plc." David will take an active role on the Ceuta Group Board supporting and building the company's strategic vision and priorities. He will also help shape the company's growth plans on an operational level to ensure Ceuta Group continues to meet client's needs today and into the future.
pharmacybiz

Ravindra Limaye:OBE honour for contribution to health sector - 0 views

  •  
    Wockhardt UK managing director Ravindra Limaye has been chosen for honorary British awards given to foreign nationals. Limaye gets the Order of the British Empire (OBE) honour for his contribution to health, particularly during the Covid-19 pandemic. The honours were announced on Thursday (13). Limaye has been the chief executive of the UK arm of the Mumbai-based pharma and biotech company Wockhardt since 2019. He previously worked for another Indian pharma company Biocon, overseeing its global commercial operations. He led the company's entry into global biosimilar markets and spearheaded its operations in the US.
pharmacybiz

Pharmacists Confidence Diminishes Due To Financial Pressure - 0 views

  •  
    Growing financial pressures has dented pharmacists' confidence, despite an anticipated increase in profits in the current year, latest Lloyds Bank Healthcare Confidence Index revealed on Tuesday (November 9). Though short-term confidence among pharmacists increased for the fifth consecutive year, ticking up from 27 to 29, the sector's long-term belief fell from -34 to -42. Martyn Kendrick, UK head of healthcare banking services at Lloyds Bank, said: "While pharmacists' confidence has declined somewhat, their short-term outlook has improved for another year, painting a picture of a sector that has begun to bounce back." He added that "pharmacists have performed an invaluable service during the lockdown, confirming their place at the heart of our communities." The index, a survey of pharmacists, GPs and dentists, has run annually since 2011 and gives a detailed overview of the sector.
pharmacybiz

HRT supply issue: 12 out of 13 HRT SSPs extended until Oct - 0 views

  •  
    To help manage the ongoing supply disruptions, the health regulators have extended to 28 October 2022, serious shortage protocols (SSPs) for 12 of the 13 hormone replacement therapies (HRT). "The only HRT SSP set to expire on 29 July 2022 is for SSP021 Premique low dose 0.3mg/1.5mg modified-release tablets. After 29 July, there will be no need to restrict quantities of Premique tablets as its supply situation has now stabilised," said PSNC. In addition, the dose equivalence advice and endorsement guidance for SSP024 and SSP025 have been updated. SSP024 and SSP025 have been updated by DHSC to provide greater clarity to pharmacists on the dose equivalences to determine the appropriate quantity to supply. Pharmacists are asked to refer to the latest SSP versions and endorsement guidance published on NHSBSA's website.
pharmacybiz

Oxford:No Evidence Vaccines Won't Protect Against Omicron - 0 views

  •  
    The University of Oxford on Tuesday said there was no evidence that vaccines would not prevent severe disease from Omicron, but that it was ready to rapidly develop an updated version of its vaccine developed with AstraZeneca if necessary. Earlier on Tuesday, the head of drugmaker Moderna said that Covid-19 shots were unlikely to be as effective against the variant, jolting global markets. The University of Oxford said that there was limited data on Omicron so far, and that it would carefully evaluate the impact of the variant on its shot, echoing an AstraZeneca statement last week. "Despite the appearance of new variants over the past year, vaccines have continued to provide very high levels of protection against severe disease and there is no evidence so far that Omicron is any different," it said in a statement.
pharmacybiz

Moderna Boss Warns Against Omicron Jab Struggle - 0 views

  •  
    Existing Covid-19 inoculations will struggle against the fast-spreading Omicron variant, the head of vaccine manufacturer Moderna warned on Tuesday (November 30), as countries ramp up vaccination programmes and impose further restrictions in an effort to curb growing concern. First reported to the World Health Organization in South Africa less than a week ago, the new strain has rapidly spread from Africa to the Pacific, and from Europe to North America as dozens of countries have announced travel restrictions. While no deaths have yet been reported from Omicron, and it could take weeks to know how infectious and how resistant the strain may prove to vaccines, its emergence underscores how besieged the world remains by Covid-19, nearly two years after the first cases were recorded. Stephane Bancel, the head of US vaccine manufacturer Moderna, told the Financial Times in an interview published today that data would be available on the effectiveness of vaccines in the two weeks' time, but that scientists were pessimistic.
pharmacybiz

PDA awareness factsheet:How to deal with stress at workplace - 0 views

  •  
    The Pharmacists' Defence Association (PDA) is playing a vital role in helping pharmacists who are dealing with stress at the workplace. It launched its new awareness factsheet 'It's Time to Address Stress' last week. The factsheet looks at the causes and symptoms of stress in the workplace and provides advice on ways pharmacists can access support and improve working conditions. The association said that it recognises the well-being services offered by employers and specialist charities such as the PDA's charity partner Pharmacist Support play an important part in helping pharmacists who may be experiencing stress. However, the PDA is also committed to working with members to challenge employers to provide well workplaces and to help them to make real impact changes. This can be done by addressing the causes of stress and fulfilling their responsibilities to their employees. It added: "Under the management of Health and Safety at Work Regulations 1999, employers are required by law to protect employees from harm. Their legal obligations include identifying hazards and risks and implementing ways to reduce or eliminate them. The PDA's new factsheet highlights the importance of employers recognising the hazards causing stress as the health and safety issues they are."
pharmacybiz

GSK,Sanofi,Haleon shares slump on Zantac litigation concerns - 0 views

  •  
    Shares in GSK, Sanofi and Haleon fell sharply on Thursday (August 11) amid growing investor concerns about US litigation focused on a heartburn drug that contained a probable carcinogen, while Johnson and Johnson has decided to end sales of talcum powder after cancer claims. GSK shares were down 6.8 per cent, Sanofi's were down 6.9 per cent and Haleon's down per cent. GSK and Sanofi at various points sold the drug - originally branded as Zantac - which US regulators ordered off the market in 2020. Haleon, spun out as an independent listed company last month, comprises consumer health assets once partly owned by GSK. The prospect of impending litigation is not new. Among other disclosures, recently-listed Haleon had highlighted the risk of such lawsuits in its prospectus. The topic has arrived in investor consciousness in recent days it seems, but has been rumbling on in the background for a few years, Deutsche Bank analysts wrote in a note.
pharmacybiz

Complete skin protection in just easy steps - 0 views

  •  
    The Intime range from incontinence experts Ontex provides maximum protection and the low hipster waist has been designed with discretion and comfort in mind, absorbing eight times its own weight. The innovative hipster shape brings a perfect fit that works with any outfit, to provide a comfortable sensation and maximum wear-ability for the user. The slim core means that women will never feel a bulky sensation when wearing Intime. Prices start from £8.99 for a pack of 12 and can be purchased via the AAH ordering platform, or through your local AAH contact.
pharmacybiz

Mark Drakeford:Welsh Minister Diwali celebrations in Cardiff - 0 views

  •  
    Welsh First Minister Mark Drakeford joined Diwali celebration at the official Indian government in Cardiff on 26 October. The 68-year-old Labour politician joined in with the traditional Indian dancing at Glamorgan Cricket club in Pontcanna, Cardiff, for the Hindu celebration of Diwali. He was joined by Health Minister Baroness Eluned Morgan and Indian Honorary Consul Raj Aggarwal, who organised the event which was attended by hundreds of guests and included some exuberant celebrations. Speaking at the event Raj Aggarwal spoke about the excitement in the British Asian community to have the UK's first ever Asian Prime Minister.
pharmacybiz

Jeremy Meader resigns as managing director of Numark - 0 views

  •  
    Jeremy Meader has resigned as managing director of Numark after five years on the job, and having lead the wider PHOENIX group's sales and marketing teams for about eight years. A press release issued on Wednesday (February 1) said Mr Meader "has decided to leave the business to pursue his career outside of the PHOENIX group", the owner of Numark. It said: "PHOENIX thanks Jeremy for his commitment and dedication over the years and wishes him all the best for his professional and private future." Previous to joining PHOENIX, Mr Meader was head of sales at Alliance Healthcare, a role he took up in 2012 after serving GSK's Consumer Healthcare division for over 13 years in various capacity.
pharmacybiz

Perrigo restructures management level:Strengthen local brands - 0 views

  •  
    Perrigo, one of the world's largest providers of self-care products has appointed Ronald van Workum as Sales Director Germany, Customer Strategy & Implementation DACH Cluster. van Workum will continue to drive the successful integration of HRA Pharma into the Perrigo network, with a focus on well-known brands such as Abtei, Compeed and Granu Fink. He most recently held the position of Head of Key Account Management for Perrigo in Europe, based in the Netherlands. Prior to joining Perrigo he worked for Procter & Gamble in several countries, including Singapore, and in various functions, including: Market Strategy Planning Manager for the Gillette brand; and in Europe as multifunctional Team Leader Emerging Channels. The company also announced Tobias Geiger has been promoted from his role as Finance Director of the Perrigo DACH Cluster, which he held since April 2020, to General Manager of the Perrigo DACH Cluster. During this time, he successfully supported the implementation and stabilisation of the DACH cluster. He also led several business optimisations with his teams, such as the implementation of SAP in Switzerland, process digitalisation and the creation of a DACH Finance Business Partner Model. Before joining Perrigo, Geiger worked for Sanofi for more than 10 years in various leadership positions in DACH and in Latin America.
pharmacybiz

Diane DiGangi Trench: BGMA appoints its new vice-chair - 0 views

  •  
    The British Generic Manufacturers Association (BGMA) has elected Diane DiGangi Trench to be its new vice-chair. DiGangi Trench takes up the position replacing Xiromed's Peter Ballard and in 12-months' time will assume the association's chair role from Accord's Peter Kelly. With over 25 years of pharmaceutical industry experience, DiGangi Trench has held a number of senior commercial roles including stints with Takeda and Astra Zeneca. She joined Sandoz in 2018 in the US, where she served as Vice-President, Market Access and Patient Services. In 2021, she became the head of Sandoz' UK business and in her two years in role, she has led the organisation through a post-COVID recovery and growth phase to prepare for the proposed spin out of the company from its parent, Novartis, expected later this year. She said: "It's a great honor to take on the role of Vice Chair of the BGMA. The success of the generics and biosimilar industry is essential to the functioning of the NHS. Generic medicines fill four out of five UK prescriptions and biosimilars enable the NHS to expand access to more patients. I am passionate about increasing the sustainability of our industry so we can continue to play our vital part in the health of the nation." Mark Samuels, BGMA chief executive, said: "We are extremely fortunate to be able to call upon the expertise of Diane who has already added significant value through her role on the BGMA board and leadership of a key strategic committee.
pharmacybiz

Yusuf Hamied:Cambridge college named after Cipla chief - 0 views

  •  
    A new residential building named after Dr Yusuf Hamied has opened at Christ's College, Cambridge, where the head of the Indian pharma giant, Cipla, was an undergraduate and then PhD chemistry student between 1954 and 1960. In more than 800 years that Cambridge University has been in existence, this is the first time an entire building has been named after an Indian. The "grand opening of Yusuf Hamied Court" at Christ's was presided over by Lord Simon McDonald, the Master of the College, and attracted about 25 leading scientists, mostly chemistry professors. Professor Sir Venkatraman Ramakrishnan, a chemistry Nobel Prize winner and a former president of the Royal Society, was also present at the event earlier this month, as well as Dr Anthony Freeling, the acting vice-chancellor of Cambridge University, and the chemist Dame Mary Archer, wife of the best-selling novelist Jeffrey Archer. Hamied and McDonald posed for photographs in front of the "entirely green" four-storey building, where the 64 rooms for postgraduates and fellows from around the world will rely on heat exchangers, instead of gas.
pharmacybiz

Haleon not surprised by Pfizer stake sale plans, says CFO - 0 views

  •  
    Pfizer's plan to sell its Haleon stake is not a surprise, the consumer health company's finance chief Tobias Hestler told Reuters on Wednesday (3 May). London-listed Haleon was carved out as an independent company in July and comprises consumer health assets once owned by GSK and Pfizer. Pfizer, which has a 32% stake in the maker of Sensodyne toothpaste and Panadol painkillers, told the Financial Times on Tuesday that it intends to offload that stake in a "slow and methodical" manner within months. Hestler said Pfizer has long been clear about its intention to sell off the stake, suggesting that the reason the potential of the selloff has gained traction is because the selling window opens around the time that Haleon's results are announced. "This will happen every quarter from now until they're sold off…this is just what's expected," he said, adding: "If I get a courtesy call the evening before they do it then that would be nice, but they don't even have to do that." Shares of the world's biggest standalone consumer health business were down more than 3% in early trading.
pharmacybiz

Hit by Covid, EU population shrinks for second year running - 0 views

  •  
    The European Union's population shrank for a second year running last year, the bloc's statistics office said on Monday, as the region reels from over two million deaths from the coronavirus. According to Eurostat, the population of the 27 countries that make up the bloc fell by close to 172,000 from the previous year and over 656,000 from January 2020. "In 2020 and 2021 the positive net migration no longer compensated for the negative natural change in the EU and, as a consequence, the EU total population has been decreasing," it said, pointing to impacts from the pandemic. The number of deaths began outstripping births in the EU a decade ago, but immigration from outside the bloc helped offset the gap until the first year of the pandemic. The previous time the EU had registered a fall in population was in 2011 - the only other time since 1960 - but this rapidly picked up due to net migration.
pharmacybiz

David Webb opens health hub at Hindu festival - 0 views

  •  
    England's chief pharmaceutical officer David Webb on Friday (July 22) officially opened a community health hub at a Hindu temple in west London. The interactive health hub, which was built as part of the 'Festival of Inspiration' - a 10-day cultural celebration of the UK's South Asian Hindu communities, will provide visitors with free health awareness and well-being advice. The cultural extravaganza, which ends on July 31, draws upon the inspiring life, work and wisdom of His Holiness Pramukh Swami Maharaj, one of the world's great spiritual leaders and creator of the iconic Neasden Temple. Sharing his reflection on the festival and the health hub, Webb said: "It's been an absolute pleasure to visit and be a part of the Festival of Inspiration on the hundredth centenary of His Holiness. I've been really impressed by the extensive programme of engagement with the community to improve health and wellbeing." Senior pharmacist Prof Mahendra Patel accompanied Webb during the opening ceremony.
pharmacybiz

BioNTech cancer vaccines clinical trials start this year UK - 0 views

  •  
    Clinical trials for BioNTech's cancer vaccines should start this year in Britain, marking an important step towards their possible sale on the open market, the German company's top executive Ugur Sahin told magazine Der Spiegel. BioNTech, known for its COVID vaccine with U.S. partner Pfizer, is currently deciding which types of cancer it wants to test its personalized cancer immunotherapies on and the locations where it will conduct the trials, Sahin said. The company wants these therapies, which are based on messenger RNA (mRNA) technology similar to the one that underpins its COVID-19 vaccine, to soon become a regular treatment for cancer patients. "We believe that this should be possible for large amounts of patients before 2030," Sahin said.
« First ‹ Previous 81 - 100 of 118 Next ›
Showing 20 items per page